


A. A compound of Formula I



or a pharmaceutically acceptable salt thereof, wherein


X¹ is Cl or F;

[0275] X² is CH₂, O, S, or NH;

R¹, R², R⁴, R⁵, and R⁶ are each independently H, alkoxy, hydroxyl, thiol, or halo; and

R³ is H, alkoxy, amino, hydroxyl, thiol, or halo.

B. The compound of Paragraph A, wherein the compound is of Formula II:



or a pharmaceutically acceptable salt thereof.

C. The compound of Paragraph A or Paragraph B, wherein when X² is O and R⁴, R⁵, and R⁶ are each independently H, then

R¹ and R² are each independently H, alkoxy, or halo; and R³ is H, alkoxy, amino, or halo.

D. The compound of any one of Paragraphs A-C, wherein at least two of R¹, R², and R³ are each independently H.


E. The compound of any one of Paragraphs A-D, wherein at least two of R⁴, R⁵, and R⁶ are each independently H.

F. The compound of any one of Paragraphs A-E, wherein when at least one of R¹, R², and R³ is hydroxyl, then at least one of R⁴, R⁵, and R⁶ is not H.

G. The compound of any one of Paragraphs A-F, wherein when one of R¹, R², and R³ is hydroxyl and the remaining R¹, R², and R³ each independently H, then at least one of R⁴, R⁵, and R⁶ is not H.

H. The compound of any one of Paragraphs A-F, wherein R¹, R², and R³ are each independently H.

I. A compound of Formula III



or a pharmaceutically acceptable salt thereof, wherein

X³ is Cl or F;

[0276] X⁴ is CH₂, O, S, or NH; and

R⁷ is alkoxy, hydroxyl, thiol, or halo.

J. A composition comprising a compound of any one of Paragraphs A-I and a pharmaceutically acceptable carrier.

K. A pharmaceutical composition for treating metastatic cancer, the composition comprising an effective amount of the compound of any one of Paragraphs A-I and a pharmaceutically acceptable excipient.

L. The pharmaceutical composition of Paragraph K, wherein the cancer is multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, or prostate cancer.

M. The pharmaceutical composition of Paragraph K or Paragraph L, wherein the pharmaceutical composition is packaged in unit dosage form.

N. A method for inhibiting cell motility of a cancer cell, the method comprising contacting the cancer cell with a compound of any one of Paragraphs A-I.

O. The method of Paragraph N, wherein the cancer cell is a metastatic multiple myeloma cancer cell, a metastatic melanoma cancer cell, a metastatic lung cancer cell, a metastatic hepatocellular carcinoma cell, a metastatic breast cancer cell, or a metastatic prostate cancer cell.

P. The method of Paragraph N or Paragraph O, wherein the method comprises contacting the cell with an effective amount of the compound.

Q. The method of any one of Paragraphs N-P, wherein the cancer cell is not within a patient.

R. A method of treating a patient or animal suffering from metastatic cancer, the method comprising administration of an effective amount of a compound of any one of Paragraphs A-I to the patient or animal suffering from the metastatic cancer.

S. The method of Paragraph R, wherein administration of the effective amount of the compound to the patient or animal treats the patient or animal suffering from the metastatic cancer.

T. The method of Paragraph R or Paragraph S, wherein the metastatic cancer is multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, or prostate cancer.

U. The method of any one of Paragraphs R-T, wherein the administration comprises oral administration, parenteral administration, or nasal administration.